1
|
Dahora LC, Jin C, Spreng RL, Feely F, Mathura R, Seaton KE, Zhang L, Hill J, Jones E, Alam SM, Dennison SM, Pollard AJ, Tomaras GD. IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. Front Immunol 2019; 10:2582. [PMID: 31781100 PMCID: PMC6852708 DOI: 10.3389/fimmu.2019.02582] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 10/17/2019] [Indexed: 01/09/2023] Open
Abstract
Vaccination against Salmonella Typhi using the Vi capsular polysaccharide, a T-cell independent antigen, can protect from the development of typhoid fever. This implies that antibodies to Vi alone can protect in the absence of a T cell-mediated immune response; however, protective Vi antibodies have not been well-characterized. We hypothesized that variability in the biophysical properties of vaccine-elicited antibodies, including subclass distribution and avidity, may impact protective outcomes. To interrogate the relationship between antibody properties and protection against typhoid fever, we analyzed humoral responses from participants in a vaccine efficacy (VE) trial using a controlled human infection model (CHIM) who received either a purified Vi polysaccharide (Vi-PS) or Vi tetanus toxoid conjugate (Vi-TT) vaccine followed by oral challenge with live S. Typhi. We determined the avidity, overall magnitude, and vaccine-induced fold-change in magnitude from before immunization to day of challenge of Vi IgA and IgG subclass antibodies. Amongst those who received the Vi-PS vaccine, Vi IgA magnitude (FDR p = 0.01) and fold-change (FDR p = 0.02) were significantly higher in protected individuals compared with those individuals who developed disease ("diagnosed"). In the Vi-TT vaccine group, the responses of protected individuals had higher fold-change in Vi IgA (FDR p = 0.06) and higher Vi IgG1 avidity (FDR p = 0.058) than the diagnosed Vi-TT vaccinees, though these findings were not significant at p < 0.05. Overall, protective antibody signatures differed between the Vi-PS and Vi-TT vaccines, thus, we conclude that although the Vi-PS and Vi-TT vaccines were observed to have similar efficacies, these vaccines may protect through different mechanisms. These data will inform studies on mechanisms of protection against typhoid fever, including identification of antibody effector functions, as well as informing future vaccination strategies.
Collapse
Affiliation(s)
- Lindsay C Dahora
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States.,Department of Immunology, Duke University, Durham, NC, United States
| | - Celina Jin
- Oxford Vaccine Group, Department of Paediatrics, The NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
| | - Rachel L Spreng
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States.,Department of Medicine, Duke University, Durham, NC, United States
| | - Frederick Feely
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States.,Department of Surgery, Duke University, Durham, NC, United States
| | - Ryan Mathura
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States.,Department of Surgery, Duke University, Durham, NC, United States
| | - Kelly E Seaton
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States.,Department of Surgery, Duke University, Durham, NC, United States
| | - Lu Zhang
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States.,Department of Surgery, Duke University, Durham, NC, United States
| | - Jennifer Hill
- Oxford Vaccine Group, Department of Paediatrics, The NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
| | - Elizabeth Jones
- Oxford Vaccine Group, Department of Paediatrics, The NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
| | - S Munir Alam
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States.,Department of Medicine, Duke University, Durham, NC, United States.,Department of Pathology, Duke University, Durham, NC, United States
| | - S Moses Dennison
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States.,Department of Surgery, Duke University, Durham, NC, United States
| | - Andrew J Pollard
- Oxford Vaccine Group, Department of Paediatrics, The NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
| | - Georgia D Tomaras
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States.,Department of Immunology, Duke University, Durham, NC, United States.,Department of Surgery, Duke University, Durham, NC, United States.,Molecular Genetics and Microbiology, Duke University, Durham, NC, United States
| |
Collapse
|
2
|
Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. J Natl Cancer Inst 2017; 109:2982600. [PMID: 28376158 PMCID: PMC5441294 DOI: 10.1093/jnci/djw261] [Citation(s) in RCA: 129] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Accepted: 10/04/2016] [Indexed: 12/14/2022] Open
Abstract
Immunotherapy is an important breakthrough in cancer. US Food and Drug Administration-approved immunotherapies for cancer treatment (including, but not limited to, sipuleucel-T, ipilimumab, nivolumab, pembrolizumab, and atezolizumab) substantially improve overall survival across multiple malignancies. One mechanism of action of these treatments is to induce an immune response against antigen-bearing tumor cells; the resultant cell death releases secondary (nontargeted) tumor antigens. Secondary antigens prime subsequent immune responses (antigen spread). Immunotherapy-induced antigen spread has been shown in clinical studies. For example, in metastatic castration-resistant prostate cancer patients, sipuleucel-T induced early immune responses to the immunizing antigen (PA2024) and/or the target antigen (prostatic acid phosphatase). Thereafter, most patients developed increased antibody responses to numerous secondary proteins, several of which are expressed in prostate cancer with functional relevance in cancer. The ipilimumab-induced antibody profile in melanoma patients shows that antigen spread also occurs with immune checkpoint blockade. In contrast to chemotherapy, immunotherapy often does not result in short-term changes in conventional disease progression end points (eg, progression-free survival, tumor size), which may be explained, in part, by the time taken for antigen spread to occur. Thus, immune-related response criteria need to be identified to better monitor the effectiveness of immunotherapy. As immunotherapy antitumor effects take time to evolve, immunotherapy in patients with less advanced cancer may have greater clinical benefit vs those with more advanced disease. This concept is supported by prostate cancer clinical studies with sipuleucel-T, PSA-TRICOM, and ipilimumab. We discuss antigen spread with cancer immunotherapy and its implications for clinical outcomes.
Collapse
Affiliation(s)
- James L Gulley
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Ravi A Madan
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | | | - Peter Mulders
- Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | | | | | - Charles G Drake
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and The Brady Urological Institute, Baltimore, MD, USA
| |
Collapse
|
3
|
Bavaro T, Tengattini S, Piubelli L, Mangione F, Bernardini R, Monzillo V, Calarota S, Marone P, Amicosante M, Pollegioni L, Temporini C, Terreni M. Glycosylation of Recombinant Antigenic Proteins from Mycobacterium tuberculosis: In Silico Prediction of Protein Epitopes and Ex Vivo Biological Evaluation of New Semi-Synthetic Glycoconjugates. Molecules 2017; 22:molecules22071081. [PMID: 28661444 PMCID: PMC6152100 DOI: 10.3390/molecules22071081] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Revised: 06/23/2017] [Accepted: 06/23/2017] [Indexed: 01/25/2023] Open
Abstract
Tuberculosis is still one of the most deadly infectious diseases worldwide, and the use of conjugated antigens, obtained by combining antigenic oligosaccharides, such as the lipoarabinomannane (LAM), with antigenic proteins from Mycobacterium tuberculosis (MTB), has been proposed as a new strategy for developing efficient vaccines. In this work, we investigated the effect of the chemical glycosylation on two recombinant MTB proteins produced in E. coli with an additional seven-amino acid tag (recombinant Ag85B and TB10.4). Different semi-synthetic glycoconjugated derivatives were prepared, starting from mannose and two disaccharide analogs. The glycans were activated at the anomeric position with a thiocyanomethyl group, as required for protein glycosylation by selective reaction with lysines. The glycosylation sites and the ex vivo evaluation of the immunogenic activity of the different neo-glycoproteins were investigated. Glycosylation does not modify the immunological activity of the TB10.4 protein. Similarly, Ag85B maintains its B-cell activity after glycosylation while showing a significant reduction in the T-cell response. The results were correlated with the putative B- and T-cell epitopes, predicted using a combination of in silico systems. In the recombinant TB10.4, the unique lysine is not included in any T-cell epitope. Lys30 of Ag85B, identified as the main glycosylation site, proved to be the most important site involved in the formation of T-cell epitopes, reasonably explaining why its glycosylation strongly influenced the T-cell activity. Furthermore, additional lysines included in different epitopes (Lys103, -123 and -282) are also glycosylated. In contrast, B-cell epitopic lysines of Ag85B were found to be poorly glycosylated and, thus, the antibody interaction of Ag85B was only marginally affected after coupling with mono- or disaccharides.
Collapse
Affiliation(s)
- Teodora Bavaro
- Department of Drug Sciences, University of Pavia, via Taramelli 12, I-27100 Pavia, Italy.
| | - Sara Tengattini
- Department of Drug Sciences, University of Pavia, via Taramelli 12, I-27100 Pavia, Italy.
| | - Luciano Piubelli
- Department of Biotechnology and Life Sciences, University of Insubria, via J.H. Dunant 3, I-21100 Varese, Italy.
- The Protein Factory, Interuniversity Centre Politecnico of Milano and University of Insubria, via Mancinelli 7, I-20131 Milano, Italy.
| | - Francesca Mangione
- Microbiology and Virology Unit, IRCCS San Matteo Hospital Foundation, viale Camillo Golgi 19, I-27100 Pavia, Italy.
| | - Roberta Bernardini
- Department of Biomedicine and Prevention and Animal Technology Station, University of Rome "Tor Vergata", via Montpellier 1, I-00133 Roma, Italy.
| | - Vincenzina Monzillo
- Microbiology and Virology Unit, IRCCS San Matteo Hospital Foundation, viale Camillo Golgi 19, I-27100 Pavia, Italy.
- Infection Disease Unit, Internal Medicine and Medical Therapy Department, University of Pavia, via Aselli 43/45, I-27100 Pavia, Italy.
| | - Sandra Calarota
- Microbiology and Virology Unit, IRCCS San Matteo Hospital Foundation, viale Camillo Golgi 19, I-27100 Pavia, Italy.
| | - Piero Marone
- Microbiology and Virology Unit, IRCCS San Matteo Hospital Foundation, viale Camillo Golgi 19, I-27100 Pavia, Italy.
| | - Massimo Amicosante
- Department of Biomedicine and Prevention and Animal Technology Station, University of Rome "Tor Vergata", via Montpellier 1, I-00133 Roma, Italy.
| | - Loredano Pollegioni
- Department of Biotechnology and Life Sciences, University of Insubria, via J.H. Dunant 3, I-21100 Varese, Italy.
- The Protein Factory, Interuniversity Centre Politecnico of Milano and University of Insubria, via Mancinelli 7, I-20131 Milano, Italy.
| | - Caterina Temporini
- Department of Drug Sciences, University of Pavia, via Taramelli 12, I-27100 Pavia, Italy.
| | - Marco Terreni
- Department of Drug Sciences, University of Pavia, via Taramelli 12, I-27100 Pavia, Italy.
| |
Collapse
|
4
|
Jacobs AJ, Mongkolsapaya J, Screaton GR, McShane H, Wilkinson RJ. Antibodies and tuberculosis. Tuberculosis (Edinb) 2016; 101:102-113. [PMID: 27865379 PMCID: PMC5120988 DOI: 10.1016/j.tube.2016.08.001] [Citation(s) in RCA: 101] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Revised: 07/19/2016] [Accepted: 08/04/2016] [Indexed: 12/16/2022]
Abstract
Tuberculosis (TB) remains a major public health problem internationally, causing 9.6 million new cases and 1.5 million deaths worldwide in 2014. The Bacillus Calmette-Guérin vaccine is the only licensed vaccine against TB, but its protective effect does not extend to controlling the development of infectious pulmonary disease in adults. The development of a more effective vaccine against TB is therefore a pressing need for global health. Although it is established that cell-mediated immunity is necessary for the control of latent infection, the presupposition that such immunity is sufficient for vaccine-induced protection has recently been challenged. A greater understanding of protective immunity against TB is required to guide future vaccine strategies against TB. In contrast to cell-mediated immunity, the human antibody response against M.tb is conventionally thought to exert little immune control over the course of infection. Humoral responses are prominent during active TB disease, and have even been postulated to contribute to immunopathology. However, there is evidence to suggest that specific antibodies may limit the dissemination of M.tb, and potentially also play a role in prevention of infection via mucosal immunity. Further, antibodies are now understood to confer protection against a range of intracellular pathogens by modulating immunity via Fc-receptor mediated phagocytosis. In this review, we will explore the evidence that antibody-mediated immunity could be reconsidered in the search for new vaccine strategies against TB.
Collapse
Affiliation(s)
- Ashley J Jacobs
- Department of Medicine, Imperial College London, W2 1PG, United Kingdom; Clinical Infectious Diseases Research Initiative and Department of Medicine, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory 7925, South Africa.
| | | | - Gavin R Screaton
- Department of Medicine, Imperial College London, W2 1PG, United Kingdom
| | - Helen McShane
- The Jenner Institute, University of Oxford, OX3 7DQ, United Kingdom
| | - Robert J Wilkinson
- Department of Medicine, Imperial College London, W2 1PG, United Kingdom; Clinical Infectious Diseases Research Initiative and Department of Medicine, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory 7925, South Africa; The Francis Crick Institute, London NW1 2AT, United Kingdom
| |
Collapse
|
5
|
Sotnikov DV, Zherdev AV, Avdienko VG, Dzantiev BB. Immunochromatographic assay for serodiagnosis of tuberculosis using an antigen–colloidal gold conjugate. APPL BIOCHEM MICRO+ 2015. [DOI: 10.1134/s0003683815080062] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
6
|
Afzal M, Khurshid S, Khalid R, Paracha RZ, Khan IH, Akhtar MW. Fusion of selected regions of mycobacterial antigens for enhancing sensitivity in serodiagnosis of tuberculosis. J Microbiol Methods 2015; 115:104-11. [PMID: 26068786 DOI: 10.1016/j.mimet.2015.06.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Revised: 06/04/2015] [Accepted: 06/06/2015] [Indexed: 11/27/2022]
Abstract
Serodiagnosis of tuberculosis requires detection of antibodies against multiple antigens of Mycobacterium tuberculosis, because antibody profiles differ among the patients. Using fusion proteins with epitopes from two or more antigens would facilitate in the detection of multiple antibodies. Fusion constructs tn1FbpC1-tnPstS1 and tn2FbpC1-tnPstS1 were produced by linking truncated regions of variable lengths from FbpC1 to the N-terminus of the truncated PstS1. Similarly a truncated fragment of HSP was linked to the N-terminus of a truncated fragment from FbpC1 to produce tnHSP-tn1FbpC1. ELISA analysis of the plasma samples of TB patients against tn2FbpC1-tnPstS1 showed 72.2% sensitivity which is nearly the same as the expected combined value for the two individual antigens. However, the sensitivity of tn1FbpC1-tnPstS1 was lowered to 60%. tnHSP-tn1FbpC1 showed 67.7% sensitivity which is slightly less than the expected combined value for the two individual antigens, but still significantly higher than that of each of the individual antigen. Data for secondary structure analysis by CD spectrometry was in reasonable agreement with the X-ray crystallographic data of the native proteins and the predicted structure of the fusion proteins. Comparative molecular modeling suggests that the epitopes of the constituent proteins are better exposed in tn2FbpC1-tnPstS1 as compared to those in tn1FbpC1-tnPstS1. Therefore, removal of the N-terminal non-epitopic region of FbpC1 from 34-96 amino acids seems to have unmasked at least some of the epitopes, resulting in greater sensitivity. The high level of sensitivity of tn2FbpC1-tnPstS1 and tnHSP-tn1FbpC1, not reported before, shows that these fusion proteins have great potential for use in serodiagnosis of tuberculosis.
Collapse
Affiliation(s)
- Madeeha Afzal
- School of Biological Sciences, University of the Punjab, Lahore 54590, Pakistan.
| | - Sana Khurshid
- School of Biological Sciences, University of the Punjab, Lahore 54590, Pakistan.
| | - Ruqyya Khalid
- School of Biological Sciences, University of the Punjab, Lahore 54590, Pakistan.
| | - Rehan Zafar Paracha
- Atta-Ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad 44000, Pakistan.
| | - Imran H Khan
- Department of Pathology and Laboratory Medicine, University of California, Davis 95616, USA.
| | - M Waheed Akhtar
- School of Biological Sciences, University of the Punjab, Lahore 54590, Pakistan.
| |
Collapse
|
7
|
Ivanyi J, Ottenhoff THM. Significance of antigen and epitope specificity in tuberculosis. Front Immunol 2014; 5:524. [PMID: 25379038 PMCID: PMC4206936 DOI: 10.3389/fimmu.2014.00524] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Accepted: 10/06/2014] [Indexed: 11/13/2022] Open
Affiliation(s)
- Juraj Ivanyi
- Guy's Hospital Campus of Kings College London , London , UK
| | - Tom H M Ottenhoff
- Department of Infectious Diseases, Leiden University Medical Center , Leiden , Netherlands
| |
Collapse
|